Aardvark Therapeutics Inc [AARD] stock prices are up 7.19% to $12.08 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AARD shares have gain 7.00% over the last week, with a monthly amount glided 15.82%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aardvark Therapeutics Inc [NASDAQ: AARD] stock has seen the most recent analyst activity on March 10, 2025, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $21. Previously, Morgan Stanley started tracking the stock with Overweight rating on March 10, 2025, and set its price target to $29. On March 10, 2025, Cantor Fitzgerald initiated with a Overweight rating and assigned a price target of $50 on the stock. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $22 on March 10, 2025.
The stock price of Aardvark Therapeutics Inc [AARD] has been fluctuating between $4.88 and $19.58 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Aardvark Therapeutics Inc [NASDAQ: AARD] shares were valued at $12.08 at the most recent close of the market. An investor can expect a potential return of 140.07% based on the average AARD price forecast.
Analyzing the AARD fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.15, Equity is -12.85 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.35 points at the first support level, and at 10.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.50, and for the 2nd resistance point, it is at 12.91.
Ratios To Look Out For
It’s worth pointing out that Aardvark Therapeutics Inc [NASDAQ:AARD]’s Current Ratio is 25.86. As well, the Quick Ratio is 25.86, while the Cash Ratio is 4.44.
Transactions by insiders
Recent insider trading involved Decheng Capital Global Life Sc, 10% Owner, that happened on Feb 14 ’25 when 1.25 million shares were purchased. Chief Executive Officer, Lee Tien-Li completed a deal on Feb 14 ’25 to buy 16542.0 shares. Meanwhile, Chief Financial Officer Sun Nelson bought 10000.0 shares on Feb 14 ’25.
